Product Name: BRCC36 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC-P, WB
Applications: BRCC36 antibody can be used for detection of BRCC36 by Western blot at 0.5 – 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: Predicted: 35 kDa Observed: 35 kDa
Immunogen: BRCC36 antibody was raised against a 18 amino acid synthetic peptide from near the amino terminus of human BRCC36.The immunogen is located within amino acids 20 – 70 of BRCC36.
Host Species: Rabbit
Purification: BRCC36 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 136-40-3
Product: Phenazopyridine (hydrochloride)
Buffer: BRCC36 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: BRCC36 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: BRCC36 Antibody: C6.1A, BRCC36, CXorf53, C6.1A, Lys-63-specific deubiquitinase BRCC36, BRCA1-A complex subunit BRCC36
Accession NO.: NP_077308
Protein Ino: 13236583
Official Symbol: BRCC3
Geneid: 79184
Background: BRCC36 Antibody: Together with the breast and ovarian predisposition proteins BRCA1 and BRCA2 and RAD51 and BRCC45, BRCC36 forms a holoenzyme complex that possesses a ubiquitin E3 ligase activity. Aberrant levels of BRCC36 were detected in sporadic breast tumors and depletion of either BRCC36 or BRCC45 by siRNA resulted in increased sensitivity to ionizing radiation and defects in the G2/M checkpoint, indicating that BRCC36 acts to enhance cellular survival following DNA damage. Recent experiments have shown that BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation, suggesting that BRCC36 may be an important target in the treatment of radiation-resistant breast tumors. At least two isoforms of BRCC36 are known to exist.
PubMed ID:http://aac.asm.org/content/42/5/1127.abstract
